2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
10/22/14Chiasma Continues Development and Commercialization of Oral Octreotide
Jerusalem, Israel, October 22, 2014 - Chiasma recently announced its plan to independently lead the development and commercialization of Oral Octreotide (formerly Octreolin or OOA). Chiasma is an innovative pharmaceutical company that uses its TPE system to switch injectable drugs to oral delivery and identify new treatment options. Its work with Oral Octreotide is aimed at providing patients with acromegaly an alternative to the current treatment standard of lifelong injec... 
Printer Friendly Version

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.